One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis.

Bente Glintborg Ulf LindströmDaniela Di GiuseppeSella Aarrestad ProvanBjorn GudbjornssonMerete Lund HetlandBrigitte MichelsenJohan Karlsson WallmanKalle AaltonenAnna-Mari HokkanenDan NordströmTanja Schjødt JørgensenRebekka Lund HansenArni Jon GeirssonKathrine GrønNiels Steen KroghJohan AsklingLars Erik KristensenLennart Jacobssonnull null

Published in: Arthritis care & research (2020)

Secukinumab was mainly used in biologically experienced SpA patients. Secukinumab and adalimumab performed similar in patients who had failed a first biological, although with increasing prior biological exposure, adalimumab was superior.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
end stage renal disease
disease activity
ejection fraction
newly diagnosed
chronic kidney disease
juvenile idiopathic arthritis
prognostic factors
peritoneal dialysis
patient reported outcomes
systemic lupus erythematosus